139 related articles for article (PubMed ID: 8360709)
1. Treatment of spinal epidural neuroblastoma xenografts in rats using anti-GD2 monoclonal antibody 3F8.
Bergman I; Arbit E; Rosenblum M; Larson SM; Heller G; Cheung NK
J Neurooncol; 1993 Mar; 15(3):235-42. PubMed ID: 8360709
[TBL] [Abstract][Full Text] [Related]
2. Oral (1-->3),(1-->4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma.
Cheung NK; Modak S
Clin Cancer Res; 2002 May; 8(5):1217-23. PubMed ID: 12006541
[TBL] [Abstract][Full Text] [Related]
3. Complete tumor ablation with iodine 131-radiolabeled disialoganglioside GD2-specific monoclonal antibody against human neuroblastoma xenografted in nude mice.
Cheung NK; Landmeier B; Neely J; Nelson AD; Abramowsky C; Ellery S; Adams RB; Miraldi F
J Natl Cancer Inst; 1986 Sep; 77(3):739-45. PubMed ID: 3091900
[TBL] [Abstract][Full Text] [Related]
4. Treatment of neoplastic meningeal xenografts by intraventricular administration of an antiganglioside monoclonal antibody, 3F8.
Bergman I; Barmada MA; Heller G; Griffin JA; Cheung NK
Int J Cancer; 1999 Aug; 82(4):538-48. PubMed ID: 10404068
[TBL] [Abstract][Full Text] [Related]
5. Intrathecal administration of an anti-ganglioside antibody results in specific accumulation within meningeal neoplastic xenografts in nude rats.
Bergman I; Pohl CR; Venkataramanan R; Burckart GJ; Stabin M; Barmada MA; Griffin JA; Cheung NK
J Immunother; 1999 Mar; 22(2):114-23. PubMed ID: 10093036
[TBL] [Abstract][Full Text] [Related]
6. Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2.
Miederer M; McDevitt MR; Borchardt P; Bergman I; Kramer K; Cheung NK; Scheinberg DA
Clin Cancer Res; 2004 Oct; 10(20):6985-92. PubMed ID: 15501978
[TBL] [Abstract][Full Text] [Related]
7. Disialoganglioside GD2 anti-idiotypic monoclonal antibodies.
Cheung NK; Canete A; Cheung IY; Ye JN; Liu C
Int J Cancer; 1993 May; 54(3):499-505. PubMed ID: 8509225
[TBL] [Abstract][Full Text] [Related]
8. A novel O-acetylated ganglioside detected by anti-GD2 monoclonal antibodies.
Ye JN; Cheung NK
Int J Cancer; 1992 Jan; 50(2):197-201. PubMed ID: 1730513
[TBL] [Abstract][Full Text] [Related]
9. Targeting of ganglioside GD2 monoclonal antibody to neuroblastoma.
Cheung NK; Neely JE; Landmeier B; Nelson D; Miraldi F
J Nucl Med; 1987 Oct; 28(10):1577-83. PubMed ID: 3655911
[TBL] [Abstract][Full Text] [Related]
10. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma.
Cheung NK; Lazarus H; Miraldi FD; Abramowsky CR; Kallick S; Saarinen UM; Spitzer T; Strandjord SE; Coccia PF; Berger NA
J Clin Oncol; 1987 Sep; 5(9):1430-40. PubMed ID: 3625258
[TBL] [Abstract][Full Text] [Related]
11. Disaloganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma.
Kramer K; Gerald WL; Kushner BH; Larson SM; Hameed M; Cheung NK
Med Pediatr Oncol; 2001 Jan; 36(1):194-6. PubMed ID: 11464881
[TBL] [Abstract][Full Text] [Related]
12. Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma.
Heiner JP; Miraldi F; Kallick S; Makley J; Neely J; Smith-Mensah WH; Cheung NK
Cancer Res; 1987 Oct; 47(20):5377-81. PubMed ID: 3115567
[TBL] [Abstract][Full Text] [Related]
13. Disialoganglioside G(D2) loss following monoclonal antibody therapy is rare in neuroblastoma.
Kramer K; Gerald WL; Kushner BH; Larson SM; Hameed M; Cheung NK
Clin Cancer Res; 1998 Sep; 4(9):2135-9. PubMed ID: 9748131
[TBL] [Abstract][Full Text] [Related]
14. 99mTc-monoclonal antibody radiolabeled via hydrazino nicotinamide derivative for imaging disialoganglioside G(D2)-positive tumors.
Fonti R; Cheung NK; Bridger GJ; Guo HF; Abrams MJ; Larson SM
Nucl Med Biol; 1999 Aug; 26(6):681-6. PubMed ID: 10587107
[TBL] [Abstract][Full Text] [Related]
15. Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study.
Kushner BH; Kramer K; Modak S; Cheung NK
J Clin Oncol; 2011 Mar; 29(9):1168-74. PubMed ID: 21343563
[TBL] [Abstract][Full Text] [Related]
16. Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age.
Cheung NK; Kushner BH; Cheung IY; Kramer K; Canete A; Gerald W; Bonilla MA; Finn R; Yeh SJ; Larson SM
J Clin Oncol; 1998 Sep; 16(9):3053-60. PubMed ID: 9738575
[TBL] [Abstract][Full Text] [Related]
17. Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibody.
Kushner BH; Modak S; Basu EM; Roberts SS; Kramer K; Cheung NK
Cancer; 2013 Aug; 119(15):2789-95. PubMed ID: 23633099
[TBL] [Abstract][Full Text] [Related]
18. Calculated and TLD-based absorbed dose estimates for I-131-labeled 3F8 monoclonal antibody in a human neuroblastoma xenograft nude mouse model.
Ugur O; Scott AM; Kostakoglu L; Hui TE; Masterson ME; Febo R; Sgouros G; Rosa E; Mehta BM; Fisher DR
Nucl Med Biol; 1995 Jan; 22(1):87-93. PubMed ID: 7735175
[TBL] [Abstract][Full Text] [Related]
19. Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival.
Cheung NK; Cheung IY; Canete A; Yeh SJ; Kushner B; Bonilla MA; Heller G; Larson SM
Cancer Res; 1994 Apr; 54(8):2228-33. PubMed ID: 8174131
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma.
Kushner BH; Kramer K; Cheung NK
J Clin Oncol; 2001 Nov; 19(22):4189-94. PubMed ID: 11709561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
